Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study-Reference-Cited by-同舟云学术

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

Published:2024-07 Issue:7 Volume:8 Page:
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:HemaSphere

Author:

Tomasson Michael H.¹^ORCID,Iida Shinsuke²,Niesvizky Ruben³,Mohty Mohamad⁴,Bahlis Nizar J.⁵,Martinez‐Lopez Joaquin⁶,Koehne Guenther⁷,Rodriguez‐Otero Paula⁸^ORCID,Miles Prince H.⁹,Viqueira Andrea¹⁰,Leip Eric¹¹,Conte Umberto¹²,Sullivan Sharon T.¹³,Lesokhin Alexander M.¹⁴

Affiliation:

1. Department of Internal Medicine University of Iowa Iowa City Iowa USA

2. Department of Hematology & Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

3. Multiple Myeloma Center New York–Presbyterian Hospital/Weill Cornell Medical Center New York New York USA

4. Hematology and Cellular Therapy Department Sorbonne University, Hôpital Saint‐Antoine and INSERM UMRS938 Paris France

5. Division of Hematology and Bone Marrow Transplantation, Arnie Charbonneau Cancer Institute University of Calgary Calgary Alberta Canada

6. Haematology and Haemotherapy Service Hospital Universitario 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Instituto de Investigación Hospital 12 de Octubre Madrid Spain

7. Blood & Marrow Transplant and Hematologic Oncology Miami Cancer Institute Miami Florida USA

8. Central Unit for Clinical Trials Clinica Universidad de Navarra Madrid Spain

9. Cancer Immunology and Molecular Oncology Epworth Healthcare and University of Melbourne Melbourne Victoria Australia

10. Oncology Research and Development Pfizer SLU Madrid Spain

11. Department of Clinical Research Pfizer Inc. Cambridge Massachusetts USA

12. Oncology Research and Development Pfizer Inc. New York New York USA

13. Global Product Development Pfizer Inc. Cambridge Massachusetts USA

14. Division of Hematology and Oncology Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College New York New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hem3.136

Reference10 articles.

1. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future

2. Elrexfio (elranatamab‐bcmm). Prescribing information. Pfizer;2023.

3. Elrexfio (elranatamab‐bcmm). Summary of product characteristics. Pfizer;2023.

4. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

5. van deDonkN MoreauP GarfallAL et al.Long‐term follow‐up from MajesTEC‐1 of teclistmab a B‐cell maturation antigen (BMCA) x CD3 bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). Presented at: 2023 ASCO Annual Meeting Chicago IL. Abstract 8011 June 2‐6 2023.